Abstract
Decreases in renal function lead to decreased phosphate clearance, resulting in FGF23 increases which impair 1-alpha-hydroxylase activity and activation of 25-hydroxyvitamin D. As a result, calcium absorption is decreased, leading to a compensatory secondary hyperparathyroidism. As renal function deteriorates, parathyroid hormone (PTH) action diminishes due to increasing PTH resistance further exacerbating the secondary hyperparathyroidism to maintain serum calcium. The hyperparathyroidism may cause renal osteodystrophy and increase the risk for tertiary hyperparathyroidism complicating post-renal transplant care. In addition, acid-base disturbances may lead to increased ionized calcium levels with acidemia. Management of calcium disorders in end-stage renal failure involves normalizing serum phosphate levels, preventing vitamin D deficiency, normalizing serum calcium levels and calcium-phosphate products, as well as keeping PTH levels within a range appropriate for the level of renal function. Treatment may include nonaluminum-containing phosphate binders such as sevelamer and calcium; activated vitamin D analogues such as calcitriol, doxercalciferol, and paricalcitol; as well as calcium sensing receptor agonists such as cinacalcet. Close monitoring, working with the patient’s nephrologists, to avoid hypercalcemia and adynamic bone disease is paramount. Bone-specific alkaline phosphatase, which is reflective of PTH action on the bone, may be useful in individualizing the PTH target range. Hypercalcemia developing as part of tertiary hyperparathyroidism may be managed medically, by limiting calcium and activated vitamin D intake, using cinacalcet, or surgery, with parathyroid debulking. These patients are at high risk for hungry bone syndrome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Suggested Reading
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015;132:27–39.
Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10:791–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Malabanan, A.O. (2020). Calcium Disorders in End-Stage Renal Failure Including Those on Dialysis. In: Garg, R., Hennessey, J., Malabanan, A., Garber, J. (eds) Handbook of Inpatient Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-030-38976-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-38976-5_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-38975-8
Online ISBN: 978-3-030-38976-5
eBook Packages: MedicineMedicine (R0)